Study of HU6 versus placebo for adults with MASH
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests if HU6 is safe and effective for people with MASH, a type of fatty liver disease. You will either receive HU6 or a placebo to see how it affects your liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 30 years or older.
- You have been diagnosed with MASH (a type of fatty liver disease).
- Your body mass index (BMI) is between 27 and 44.
- You are not pregnant or breastfeeding and use effective birth control if needed.
- You do not have other liver diseases like hepatitis or Wilson's disease.
- You have not used certain medications like GLP-1 agonists or high-dose vitamin E in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This trial tests if betaine, a natural substance found in foods like beets, can improve liver health in people with MASH (a type of fatty liver disease). It compares betaine to a placebo (a dummy pill) to see if it reduces liver fat and inflammation.
This trial tests a new drug called TGM-312-SC01 to see if it can help people with MASH (a type of fatty liver disease that causes inflammation and damage). It is for adults aged 18 to 70 who are otherwise healthy or have MASH.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This study tests an investigational medicine (BI 3802876) in people with early-stage liver cirrhosis due to MASH. The goal is to see if it is well tolerated and potentially helpful.
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.